Evidence map›Paper›PMID 38931265›Full record

Observational studyNutrients2024

Calcifediol or Corticosteroids in the Treatment of COVID-19: An Observational Study.

Marta Entrenas-Castillo, Luis Manuel Entrenas-Costa, María P Pata, Bernabe Jurado-Gamez, Cristina Muñoz-Corroto, Cristina Gomez-Rebollo, Estefania Mira-Padilla, Roger Bouillon, Jose Manuel Quesada-Gómez

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marta Entrenas-CastilloHospital QuironSalud Córdoba, 14004 Córdoba, Spain.ORCID 0000-0003-2264-3456
Luis Manuel Entrenas-CostaHospital QuironSalud Córdoba, 14004 Córdoba, Spain.ORCID 0000-0003-0664-5531
María P PataBiostatech, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-8035-118X
Bernabe Jurado-GamezInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, 14004 Córdoba, Spain.
Cristina Muñoz-CorrotoUnidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.ORCID 0009-0003-7401-232X
Cristina Gomez-RebolloUnidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.ORCID 0000-0001-6776-0619
Estefania Mira-PadillaUnidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.ORCID 0000-0002-8455-4945
Roger BouillonLaboratory of Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, 3000 Leuven, Belgium.
Jose Manuel Quesada-GómezInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, 14004 Córdoba, Spain.

Funding

FIBICO (Foundation of the Maimonides Institute of Biomedical Research of Cordoba) NCT05819918
6 · The paper itself

Abstract

Medical treatment of coronavirus 19 disease (COVID-19) is a therapeutic challenge. The available data strongly suggest that calcifediol treatment may reduce the severity of COVID-19, and corticosteroids are the treatment of choice worldwide for severe COVID-19. Both have a very similar action profile, and their combined use in patients may modify the contribution of each administered compound.

objectiveTo evaluate how treatment with calcifediol and/or corticosteroids in medical practice modified the need for ICU admission, death, or poor prognosis of patients hospitalized with COVID-19 during the first outbreaks. DESIGN, PATIENTS AND

settingA retrospective observational cohort study of patients admitted for COVID-19 to the Pneumology Unit of the Hospital Universitario Reina Sofía (Córdoba, Spain).

interventionsPatients were treated with calcifediol or/and corticosteroids with the best available therapy and standard care, according to clinical practice guidelines. MEASUREMENTS: Admission to the intensive care unit (ICU) or death during hospitalization and poor prognosis.

resultsSeven hundred and twenty-eight patients were included. According to the treatment received, they were included in four groups: calcifediol (

interpretationThe treatment of choice for hospitalized patients with moderate or mild COVID-19 could be calcifediol, not administering corticosteroids, until the natural history of the disease reaches a stage of hyperinflammation.

Indexed as

Adrenal Cortex HormonesCOVID-19COVID-19 Drug TreatmentSARS-CoV-2AgedAged, 80 and overFemaleGlucocorticoidsHospitalizationHumansIntensive Care UnitsMaleMiddle AgedPrognosisRetrospective StudiesSpainAdrenal Cortex HormonesGlucocorticoidscalcifediolcorticoidsCOVID-19COVID-19 drug treatmentSARS-CoV-2vitamin D

Identifiers

PMID38931265
PMCPMC11206538

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.